Coronary computed tomography angiography versus invasive coronary angiography for interventional triage in acute coronary syndrome: Design of the randomized TRACTION trial - 12/02/26
, Andreas Torp Kristensen, MD b, Kristian Eskesen, MD, PhD a, Klaus Fuglsang Kofoed, MD, PhD, DMSc b, Jesper James Linde, MD, PhD b, Henning Kelbæk c, Michael Ottesen, MD, PhD c, Keld Neland, MD, PhD c, Charlotte Kragelund, MD, PhD d, Mette Lykke Norgaard Bertelsen, MD, PhD d, Jens Dahlgaard Hove, MD, PhD e, Gorm Mørk, MD, PhD f, Ole Peter Kristiansen, MD, PhD f, Thomas Engstrøm, MD, PhD, DMSc b, Jacob Thomsen Lønborg, MD, PhD, DMSc b, Jørgen Tobias Kühl, MD, PhD, DMSc b, Signe Stelling Risom, RN, PhD a, g, h, Paul Blanche, MSc, PhD i, Niels Thue Olsen, MD, PhD bABSTRACT |
Purpose |
In patients admitted with acute coronary syndrome, invasive coronary angiography (ICA) is performed to determine which patients need revascularization. Coronary computed tomography angiography (CCTA) offers a widely available, non-invasive alternative that could reduce patient discomfort, procedural risks, and healthcare costs. The current trial aims to determine whether CCTA is noninferior to ICA in determining the interventional strategy for patients admitted with non-ST elevation acute coronary syndrome (NSTE-ACS)( Central Illustration ).
Methods |
TRACTION (Team-based Interventional Triage in Acute Coronary Syndrome Based on Noninvasive Coronary Computed Tomography Angiography Versus Invasive Coronary Angiography) is a multicenter, randomized, open-label, noninferiority trial enrolling 2,300 patients. Patients hospitalized with non-ST elevation myocardial infarction or unstable angina with ischemic changes on ECG will be randomized 1:1 to CCTA vs ICA (standard of care). In the CCTA group, a Coronary Team reviews the CCTA and clinical information to determine the interventional strategy. The primary composite endpoint is major adverse cardiac events at 1 year, comprised of all-cause mortality, nonfatal myocardial infarction, hospitalization due to refractory angina, or hospitalization due to heart failure. Secondary outcomes include cardiovascular death, revascularization, symptom status, procedure-related adverse events, and resource utilization. The trial is designed to demonstrate noninferiority if the 95% confidence interval excludes an absolute risk difference of the primary endpoint larger than 5%.
Perspectives |
If CCTA is shown to be noninferior to ICA in patients admitted with NSTE-ACS, CCTA could become the preferred management in a large group of patients. This could result in fewer patients exposed to invasive procedures and improved resource utilization.
ClinicalTrials.gov identifier: NCT06101862
Le texte complet de cet article est disponible en PDF.Plan
Vol 294
Article 107325- avril 2026 Retour au numéro
Article précédent
- Caribbean and South American team-based strategy to control hypertension (CATCH): Rationale and study design of a cluster randomized trial
- Katherine T. Mills, Trevor Ferguson, Jose P. Lopez-Lopez, Jacqueline Duncan, Paola Lanza, Allison Marshall, Mabel Reyes, Jing Chen, Amanda H. Anderson, Paul K. Whelton, Althea Bailey, Carene Lindsay, Gregorio Sanchez, Patricio Lopez-Jaramillo, Marshall Tulloch-Reid, Jiang He
- Design and rationale of CATO, a Phase IIA, randomized, double-blind, placebo-controlled study of single or repeated intravenous administration of umbilical cord-derived mesenchymal stromal cells in ischemic cardiomyopathy
- Roberto Bolli, Xian-Liang Tang, Joshua M. Hare, Raul D. Mitrani, Emerson C. Perin, João AC Lima, Barry E. Hurwitz, Dinesh Kalra, Gurnoor Singh, Russell G. Saltzman, Lina V. Caceres, Adriana Nettina, Yee-Shuan Lee, Ketty Bacallao, Edward Grant, Aisha Khan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?